Skip to main content

Table 1 Clinical characteristics and baseline biopsy evaluation in discovery and validation set

From: Discovery of Fibrinogen γ-chain as a potential urinary biomarker for renal interstitial fibrosis in IgA nephropathy

Variable

Discovery cohort

 

Validation cohort

IgAN group

(n = 18)

Healthy control

(n = 6)

P value

 

IgAN group

(n = 50)

Disease controls

(n = 42)

Healthy controls

(n = 20)

P value

IgAN vs. HC

P value

DC vs. HC

Oxford classification

         

M (M0/M1)

6/12

-

  

15/35

-

-

  

E (E0/E1)

3/15

-

  

15/35

-

-

  

S (S0/S1)

5/13

-

  

10/40

-

-

  

T (T0/T1/T2)

6/6/6

-

  

28/13/9

33/5/4

-

  

C (C0/C1/C2)

2/14/2

-

  

8/40/2

-

-

  

Female (%)

9 (50%)

3 (50%)

> 0.999

 

23(46%)

22 (52%)

10 (50%)

0.827

0.861

Age a (years)

34 (29,40)

24 (21,29)

0.172

 

34(29, 42)

40 (31, 49)

35 (28, 49)

0.131

0.195

Scr a (µmol/L)

179 (78, 261)

78 (71, 83)

0.119

 

113 (86, 196)

87 (65, 142)

74(68, 80)

0.034

0.072

eGFR a

(mL/min/1.73m2)

37.14

(25.35, 92.32)

109.7

(102.6, 114.0)

0.007

 

56.9

(30.6, 93.3)

85.6

(33.6, 106.1)

114.3

(106.8, 123.5)

< 0.001

< 0.001

Hemoglobin a (g/L)

123 (114, 124)

128 (122, 132)

0.172

 

124 (115, 140)

133 (107, 146)

131 (129, 155)

0.034

0.084

UTP (g/day) a

2.49 (1.12, 3.47)

NA

< 0.001

 

1.83 (0.80, 2.94)

3.70 (2.36, 6.96)

NA

< 0.001

< 0.001

TG (mmol/L) a

1.76 (1.36, 2.21)

2.11 (1.84, 2.00)

0.424

 

1.71 (1.07, 2.76)

2.11 (1.48, 3.10)

1.36 (0.97, 2.31)

0.080

0.028

TCHO (mmol/L) a

4.93 (4.01, 5.94)

4.15 (3.93, 4.00)

0.093

 

4.88 (3.75, 6.02)

5.73 (4.60, 7.62)

4.49 (4.10, 5.25)

0.009

0.009